LungLife AI (LSE:LLAI) Debt-to-Equity : 0.04 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LungLife AI Debt-to-Equity?

LungLife AI's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.18 Mil. LungLife AI's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was £0.09 Mil. LungLife AI's Total Stockholders Equity for the quarter that ended in Dec. 2023 was £6.25 Mil. LungLife AI's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for LungLife AI's Debt-to-Equity or its related term are showing as below:

LSE:LLAI' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.13 Med: -0.45 Max: 0.05
Current: 0.04

During the past 6 years, the highest Debt-to-Equity Ratio of LungLife AI was 0.05. The lowest was -1.13. And the median was -0.45.

LSE:LLAI's Debt-to-Equity is ranked better than
84.46% of 193 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.22 vs LSE:LLAI: 0.04

LungLife AI Debt-to-Equity Historical Data

The historical data trend for LungLife AI's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LungLife AI Debt-to-Equity Chart

LungLife AI Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-1.13

-0.94

0.04

0.05

0.04

LungLife AI Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial					0.04	0.04	0.05	0.05	0.04

Competitive Comparison of LungLife AI's Debt-to-Equity

For the Diagnostics & Research subindustry, LungLife AI's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LungLife AI's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LungLife AI's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where LungLife AI's Debt-to-Equity falls into.

LungLife AI Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

LungLife AI's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.184	+	0.089)	/	6.251
	=	0.04

LungLife AI's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.184	+	0.089)	/	6.251
	=	0.04

LungLife AI (LSE:LLAI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

LungLife AI Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of LungLife AI's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

LungLife AI (LSE:LLAI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LungLife AI Inc (LSE:LLAI) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

2545 W. Hillcrest Drive, Suite 140, Thousand Oaks, CA, USA, 91320

Website

https://www.lunglifeai.com

LungLife AI Inc is a diagnostic company focused on the early detection of lung cancer from a simple blood draw enhanced by artificial intelligence. Its LungLB Test is a blood-based tool developed to provide clinicians the information needed to make informed decisions about the management of lung nodules and lung cancer.

LungLife AI (LSE:LLAI) Headlines

No Headlines